LON:CLIN - Clinigen Group Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 807.75 -8.75 (-1.07 %) (As of 12/10/2018 08:11 AM ET)Previous CloseGBX 816.50Today's RangeGBX 801.50 - GBX 819.5052-Week RangeGBX 751.50 - GBX 1,187Volume51,252 shsAverage Volume432,646 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartDividendEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies. Its Idis Global Access segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these drugs. The company's Clinigen Specialty Pharmaceuticals segment manufactures and distributes its own and in-licensed specialist, and hospital-only medicines worldwide. It offers Ethyol for reducing the incidence of dry mouth in patients undergoing high dose radiation treatment; Cardioxane, a cardioprotective agent that is used to prevent the cardiotoxicity of anthracycline chemotherapy for patients with advanced or metastatic breast cancer; Savene and Totect, which are used as emergency treatments for extravasation at the site of injection of oncology treatment; and Foscavir, an anti-viral targeting human herpes viruses and is used primarily in bone marrow transplant patients. Its Link Healthcare business distributes pharmaceutical products in South Africa and the Asia-Pacific. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom. Receive CLIN News and Ratings via Email Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Delivery Sub-IndustryN/A SectorMedical Current SymbolLON:CLIN Previous Symbol CUSIPN/A Webwww.clinigengroup.com Phone+44-1283-495010 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees849 Outstanding SharesN/AMarket Cap£0.00 OptionableNot Optionable Clinigen Group (LON:CLIN) Frequently Asked Questions What is Clinigen Group's stock symbol? Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN." How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group? Clinigen Group declared a dividend on Thursday, September 27th. Stockholders of record on Thursday, November 8th will be paid a dividend of GBX 3.84 per share on Friday, November 30th. This represents a dividend yield of 0.46%. The ex-dividend date is Thursday, November 8th. This is a positive change from Clinigen Group's previous dividend of $1.76. The official announcement can be seen at this link. View Clinigen Group's Dividend History. How were Clinigen Group's earnings last quarter? Clinigen Group PLC (LON:CLIN) posted its quarterly earnings data on Tuesday, February, 27th. The company reported $21.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $20.30 by $0.90. The firm had revenue of $167.80 million for the quarter. View Clinigen Group's Earnings History. What price target have analysts set for CLIN? 6 brokerages have issued 12 month target prices for Clinigen Group's stock. Their predictions range from GBX 1,160 to GBX 1,470. On average, they expect Clinigen Group's stock price to reach GBX 1,265 in the next year. This suggests a possible upside of 56.6% from the stock's current price. View Analyst Price Targets for Clinigen Group. What is the consensus analysts' recommendation for Clinigen Group? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clinigen Group. Has Clinigen Group been receiving favorable news coverage? Media coverage about CLIN stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clinigen Group earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Clinigen Group's key competitors? Some companies that are related to Clinigen Group include 22nd Century Group (XXII), 3D Signatures (DXD), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acerus Pharmaceuticals (ASP), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Activecare (ACAR) and Advanced Accelerator Application (AAAP). Who are Clinigen Group's key executives? Clinigen Group's management team includes the folowing people: Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 50)Mr. Martin Abell, CFO & DirectorMs. Debra Ainge, Chief Operating OfficerMatt Parrish, Head of Investor RelationsMr. David Bryant, Director of Corp. Devel. How do I buy shares of Clinigen Group? Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Clinigen Group's stock price today? One share of CLIN stock can currently be purchased for approximately GBX 807.75. What is Clinigen Group's official website? The official website for Clinigen Group is http://www.clinigengroup.com/. How can I contact Clinigen Group? Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010. MarketBeat Community Rating for Clinigen Group (LON CLIN)Community Ranking: 3.9 out of 5 ( )Outperform Votes: 350 (Vote Outperform)Underperform Votes: 100 (Vote Underperform)Total Votes: 450MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote "Outperform" if you believe CLIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2018 by MarketBeat.com StaffFeatured Article: What is an investor looking for in an SEC filing?